Lv1
40 积分 2024-04-24 加入
A multidimensional deep ensemble learning model predicts pathological response and outcomes in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy from pretreatment CT imaging: A multicenter study
10个月前
已完结
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
10个月前
已完结
OA01.05 Neoadjuvant Nivolumab with or without Relatlimab in Resectable NSCLC: Additional Analysis and Extended Follow-up
1年前
已关闭
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
1年前
已完结
Perioperative Nivolumab in Resectable Lung Cancer
1年前
已完结
OA01.05 Neoadjuvant Nivolumab with or without Relatlimab in Resectable NSCLC: Additional Analysis and Extended Follow-up
1年前
已关闭
PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816
1年前
已完结
EP.07C.11 Adjuvant Immunotherapy for Patients with Resectable NSCLC after Pathologic Complete Response
1年前
已关闭
Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma
1年前
已关闭
皖公网安备34019202002308
